Search results
Showing 1 to 15 of 59 results for ibd
This quality standard covers diagnosing and managing inflammatory bowel disease (Crohn’s disease and ulcerative colitis) in adults, young people and children. It describes high-quality care in priority areas for improvement.
This guideline covers using colonoscopy to check for signs of bowel cancer in people aged 18 and over with ulcerative colitis or Crohn’s disease (types of inflammatory bowel disease) or adenomas (also known as polyps). It aims to prevent cancer and prolong life by offering advice on identifying early bowel cancer in adults most at risk.
PredictSURE IBD and IBDX to guide treatment of Crohn's disease (HTG610)
Evidence-based recommendations on PredictSURE IBD and IBDX for guiding treatment of Crohn’s disease.
PredictSURE IBD for inflammatory bowel disease prognosis: ulcerative colitis (MIB313)
NICE has developed a medtech innovation briefing (MIB) on PredictSURE IBD for inflammatory bowel disease prognosis: ulcerative colitis .
All NICE products on inflammatory bowel disease. Includes any guidance, advice and quality standards.
ProciseDx point-of-care platform for inflammatory bowel disease (MIB302)
NICE has developed a medtech innovation briefing (MIB) on ProciseDx point-of-care platform for inflammatory bowel disease .
NICE has developed a medtech innovation briefing (MIB) on point-of-care and home faecal calprotectin tests for monitoring treatment response in inflammatory bowel disease .
RIDASCREEN tests for monitoring infliximab in inflammatory bowel disease (MIB109)
NICE has developed a medtech innovation briefing (MIB) on RIDASCREEN tests for monitoring infliximab in inflammatory bowel disease .
Faecal calprotectin diagnostic tests for inflammatory diseases of the bowel (HTG320)
Evidence-based recommendations on faecal calprotectin tests for distinguishing between inflammatory bowel diseases (such as Crohn’s disease and ulcerative colitis) and non-inflammatory bowel diseases (such as irritable bowel syndrome).
Evidence-based recommendations on leukapheresis for inflammatory bowel disease. This involves removing a small number of white blood cells from the person’s blood.
View recommendations for HTG75Show all sections
Sections for HTG75
history of progression to colorectal cancer in people with inflammatory bowel disease (IBD) or adenomas? Any explanatory...
Evidence-based recommendations on quantitative faecal immunochemical testing to guide colorectal cancer pathway referral in primary care.
Evidence-based recommendations on therapeutic monitoring of tumour necrosis factor (TNF)-alpha inhibitors (LISA-TRACKER, IDKmonitor and Promonitor ELISA kits) in people with Crohn’s disease.
Although there is some observational evidence in people with inflammatory bowel disease (IBD), there is no evidence in...
and genetic markers, for colorectal cancer in people with inflammatory bowel disease (IBD) or adenomas. Research should be...